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Mouse transgenesis has provided fundamental insights into pancreatic cancer, but is limited
by the long duration of allele/model generation. Here we show transfection-based multi-
plexed delivery of CRISPR/Cas9 to the pancreas of adult mice, allowing simultaneous editing
of multiple gene sets in individual cells. We use the method to induce pancreatic cancer and
exploit CRISPR/Cas9 mutational signatures for phylogenetic tracking of metastatic disease.
Our results demonstrate that CRISPR/Cas9-multiplexing enables key applications, such as
combinatorial gene-network analysis, in vivo synthetic lethality screening and chromosome
engineering. Negative-selection screening in the pancreas using multiplexed-CRISPR/Cas9
confirms the vulnerability of pancreatic cells to Brca2-inactivation in a Kras-mutant context.
We also demonstrate modelling of chromosomal deletions and targeted somatic engineering
of inter-chromosomal translocations, offering multifaceted opportunities to study complex
structural variation, a hallmark of pancreatic cancer. The low-frequency mosaic pattern of
transfection-based CRISPR/Cas9 delivery faithfully recapitulates the stochastic nature of
human tumorigenesis, supporting wide applicability for biological/preclinical research.
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P
ancreatic ductal adenocarcinoma (PDAC) has one of the
most dismal prognoses of all cancer types. It is currently the
fourth leading cause of cancer-related death worldwide and
is expected to become the second within the next 20 years1.
The therapeutic opportunities of advanced disease are very
limited and five-year survival rates continued to remain at
B5–7% in the past decades. Next-generation sequencing (NGS)
of human PDAC and transposon-based genetic screening in mice
have created large catalogues of genes involved in tumour
development, but the complexity of the molecular processes
driving the disease is still far from being understood2–7. A major
challenge will be to assign biological relevance and molecular
function to these large gene sets and to understand how complex
genetic interactions drive the pathogenetic process. Likewise,
pinpointing drivers among the thousands of transcriptionally or
epigenetically dysregulated genes in a cancer is complex and
limited by the lack of tools for high-throughput functional cancer
genome analyses.
The development of methodologies to genetically target the
mouse germ line8,9 has opened tremendous opportunities for
gene function analysis. Sophisticated mouse models of pancreatic
cancer have given extensive insights into many fundamental
aspects of tumorigenesis that can only be studied at an organismal
level10. Bottlenecks and limitations of classic transgenesis are,
however, (i) the long time frames needed to generate and
intercross genetically modified mice, (ii) the difficulties to model
some aspects of the human disease (for example, the stochastic
nature of somatic mutations in adult mice), (iii) the lack of
high-throughput methods for functional interrogation of complex
genetic interactions, (iv) the confounding phenotypes emerging
in multiallelic crosses of transgenic mice generated in various
genetic backgrounds and (v) the lack of tools for efficient
modelling of the complex structural variations defining human
cancer.
The prokaryotic CRISPR/Cas9 system has recently emerged as
a powerful tool for genome engineering in mammalian cells11–17.
Using programmable 20-bp single-guide RNAs (sgRNAs),
the endonuclease Cas9 can be directed to desired genomic
positions to induce DNA double-strand breaks. These breaks
are repaired by imperfect non-homologous end joining, which
can be exploited to induce insertions or deletions (indels) for
heterozygous or homozygous gene inactivation. CRISPR/Cas9-
based manipulation of haematopoietic stem cells or cultured
epithelial cells/organoids followed by transplantation has been
performed ex vivo18–21. In addition, we and others showed
recently CRISPR/Cas9-based somatic genome editing in different
organs of mice, including the lung, liver, brain and pancreas22–29
and direct in vivo forward genetic screening29. However, most
approaches to deliver CRISPR/Cas9 in vivo have limitations, such
as the inability or low efficiency of vector multiplexing for
complex combinatorial gene editing or the high risk to induce
off-target effects due to continuous activity of the system, for
example, by virally delivered stably integrated CRISPR/Cas9.
To address these and other unsolved limitations, we have
developed an electroporation-based vector delivery approach for
multiplexed transient CRISPR/Cas9 targeting of the pancreas. We
show how this methodology can be exploited for combinatorial
gene targeting, negative-selection screening and chromosome
engineering in pancreatic cancer. This approach will facilitate
high-throughput analysis of gene function, of cancer gene
interactions and of structural variations. We also pinpoint
limitations of high-level multiplexing, providing guidance for
appropriate use of the method.
Results
Transfection-based DNA delivery to pancreatic cells. In an
attempt to co-deliver multiple CRISPR/Cas9 vectors to pancreatic
cells, we have explored the possibility of targeting the pancreas by
direct intra-pancreatic DNA injection and in vivo electroporation.
After laparotomy, the pancreas can be mobilized to make it
accessible for intraparenchymal injection of vector DNA. We
instilled 50ml of plasmid solution before applying an electric
pulse for transfection. Settings of the Nepa21 square-pulse
generator were optimized to efficiently target the local pancreatic
parenchyma (Fig. 1 and ‘Methods’ section).
To test the efficiency of transfection, we electroporated a
reporter plasmid that supports cytomegalovirus promoter
driven green fluorescent protein (GFP) expression (Fig. 2a).
The target region was labelled with endoscopic marker, allowing
identification of the electroporated pancreatic area even after
weeks (Fig. 2b). Two days post electroporation (PE), the mice
were killed and pancreatic tissue was removed to count
GFP-expressing cells. Because of the pronounced fluorescence
background in the pancreas, which often makes it difficult to
distinguish low-level GFP expression from background signal by
immunofluorescence, we have performed immunohistochemistry
(IHC) against GFP (Fig. 2c). IHC allowed densitometric and
volumetric analyses of multiple step cuts through the whole
pancreatic tissue. Two days PE, we counted an average of 750
GFP-positive cells per pancreas (Fig. 2d). GFP-expressing cells
were restricted to the electroporated area and could not be found
in the other parts of the pancreas.
Histologically, we observed a mild-to-moderate intra- and
interlobular infiltration of macrophages and neutrophils and
occasional acinar cell vacuolization at the electroporation site
at day 2 PE (Fig. 2e). Seven days PE, this focal inter- and
intralobular infiltrates contained lymphocytes and macrophages
with brownish pigment (presumably phagocytosed endoscopic
marker and cell debris) and occasional focal acinar to ductal
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Figure 1 | Electroporation-based plasmid delivery to the murine
pancreas. (a) Scheme of experimental procedures. (b) Square-pulse
generation for in vivo electroporation. Pp, poring pulses to induce pore
formation in cellular membranes. Tp, reversed-phase transfer pulses (five
prolonged peaks) for electro-kinetic transfer of DNA particles into cells.
(c) Electroporation protocol used for optimized vector delivery into
pancreatic (panc) cells.
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metaplasia was observed (Fig. 2e). Twenty-one days PE, complete
regeneration of the acinar compartment occurred. Inflammatory
reactions fully or almost entirely disappeared, with the exception
of residual accumulations of macrophages removing endoscopic
marker. Caspase-3 staining showed a marked but locally limited
increase of acinar cell apoptosis at the site of electroporation 2
days PE, whereas at day 7 PE, apoptosis rates were similar in
electroporated and non-electroporated pancreata (Fig. 2f,g).
Likewise, mild single-cell necrosis of acinar cells,
which was observed 2 days PE, was cleared by day 7 PE.
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Figure 2 | Efficiency of electroporation-based vector delivery into pancreatic cells. (a–d) Assessing vector delivery efficiency 2 days post electroporation
(PE). (a) A GFP expression vector was injected into pancreata of wild-type mice. Two days PE, the mice were killed and pancreata analysed for transiently
expressed GFP. (b) Endoscopic marker was used for marking of the electroporated area to allow its identification at necropsy (red arrow). Sp, spleen.
Panc, pancreas. (c) IHC against GFP showing positive acinar cells at the site of electroporation. Note the low frequency of GFP-positive (pos.) cells. Scale
bars, 50mm (left), 10mm (right). (d) Absolute numbers of GFP-positive cells in electroporated pancreata of indicated mice. (e) Pancreatic histopathology at
2, 7 and 21 days PE. Top panels: haematoxylin and eosin staining 2 days PE showing slight-to-moderate inter- and intralobular infiltration of macrophages
and neutrophils at the site of electroporation. Few acinar cells show cytoplasmic vacuolization. Middle panels: moderate interlobular infiltration with
macrophages, neutrophils and lymphocytes 7 days PE. Bottom panels: complete regeneration of the acinar cell compartment and disappearance of
inflammatory response in a mouse 3 weeks PE. In all the pictures, dark pigment originating from the endoscopic marker is cleared by macrophages (black
accumulations of cells). Black arrow heads indicate the magnified areas. Scale bars, top left 200mm, mid/bottom left 500mm and right column 50mm.
(f–g) IHC of caspase-3 for quantification of apoptosis 2 and 7 days PE. (f) Caspase-3-positive cells at the site of electroporation (top) and the surrounding
normal pancreatic tissue (bottom). Arrow heads indicate apoptotic cells. Scale bars, 50mm. (g) Enumeration of caspase-3-positive cells. Graph shows
mean±s.e.m. (h–j) Assessing the number of long-term surviving cells 7 days PE. (h) A Cre recombinase expression vector was electroporated
into pancreata of Rosa26mT/mG mice to induce recombination of the Rosa26mT/mG reporter allele. (i) Conversion of membranous red to cytoplasmic/
membranous green fluorescence in acinar cells of electroporated pancreata. Scale bars, 50mm (left) and 10 mm (right). Note the low number of cells
with mT/mG conversion. (j) Absolute numbers of green fluorescent cells in pancreata of indicated mice.
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All together, these results show that the electroporation protocol
causes only mild tissue damage. Nevertheless, this could, in
principle, result in the loss of successfully electroporated cells.
The number of ‘long-term survivors’ among the successfully
transfected cells can, however, not be determined in the
experiments described so far because the GFP-expressing
plasmids are lost over time.
To address this issue, we next electroporated a phosphoglyce-
rate kinase 1 (PGK)-Cre expression vector into pancreata of
Rosa26mT/mG knock-in mice (Fig. 2h). This allele supports whole-
body red fluorescence from a membrane-targeted tdTomato (mT)
cassette, which is flanked by loxP sites30. Cre-mediated excision
of the mT cassette permits expression of a membrane-targeted
EGFP (mG) cassette located just downstream. This double-
fluorescent system allows direct visualization of both recombined
and non-recombined cells at single cell resolution. We used this
allele as a reporter to determine the number of successfully
transfected long-term surviving pancreatic cells. To this end, we
collected pancreata from mice electroporated with PGK-Cre or
control vectors 7 days PE and performed endogenous
fluorescence-based quantification of cells converted from mT to
mG (Fig. 2i,j). Although GFP-positive cells could not be observed
upon administration of control vectors (n¼ 3 mice), we found
that an average of 120 cells per pancreas exhibited a mT to mG
switch in mice receiving PGK-Cre vector. To examine Cre-
mediated recombination at the genetic level, we performed PCR-
based amplification and sequencing of the recombined mT/mG
allele (Supplementary Fig. 1). As expected, Cre electroporation
resulted in recombination of the mT/mG allele, which was,
however, only detectable by nested PCR, reflecting its low
frequency. No mT/mG conversion was detectable in pancreata
electroporated with a control plasmid, confirming the lack of
spontaneous recombination.
Because excessive amounts of Cre protein can be toxic31
(which might be the case in the unlikely scenario of extensive
Cre plasmid delivered to a cell), it cannot be fully excluded that
the number of successfully transfected cells is slightly
underestimated in this experiment. However, by combining the
data from the transient GFP delivery approach and the mT/mG
long-term conversion experiments, we can unequivocally
conclude that only a very small fraction of pancreatic cells
(maximum a few hundred cells per organ) is targeted and
survives in the long-term. We therefore suggest that these
electroporation settings for CRISPR/Cas9 delivery might be
optimal to induce low-frequency mosaic targeting of somatic
cells, a fundamental aspect of sporadic human tumorigenesis.
Pancreatic cancer induction by multiplexed CRISPR/Cas9.
Another major motivation for developing an electroporation-
based approach for CRISPR/Cas9 vector delivery was our goal to
achieve CRISPR/Cas9 multiplexing. We anticipated that electro-
phoretic transfection could allow simultaneous delivery of mul-
tiple sgRNAs to individual cells. This is difficult or (for high-level
multiplexing) even impossible to be achieved by the use of viral
delivery approaches. We have chosen to target two neutral genetic
loci as well as a set of 13 tumour-suppressor genes, which were
previously reported to be involved in pancreatic tumorigenesis,
albeit at very different frequencies (Fig. 3a and Supplementary
Table 1). sgRNAs were cloned into a modified pX330 (refs 15,29)
vector, which supports expression of Cas9 and sgRNAs by the
chicken beta actin (Cbh) and U6 promoters, respectively
(Fig. 3b). We tested multiple sgRNAs per locus by transiently
transfecting a mouse pancreatic cancer cell line with respective
vectors. sgRNAs associated with uniform high cleavage
efficiencies were selected for further in vivo experimentation.
Fig. 3a shows Surveyor assays of these selected sgRNAs.
Over 90% of human pancreatic cancers have KRAS mutations
and pancreas-specific KrasG12D expression in Ptf1aCre/þ (ref. 32);
KrasLSL-G12D/þ (ref. 33; PK) mice induces PDAC, albeit after
long time periods. We observed a median survival of 472 days
(range of 263 to 844 days; n¼ 55). To explore the feasibility of
CRISPR/Cas9-based tumour-suppressor gene targeting in this
model, we performed direct DNA injection and electroporation to
co-deliver 15 CRISPR/Cas9 vectors expressing the different
sgRNAs. Control mice were electroporated with two ‘neutral’
sgRNAs targeting intronic positions of the Rosa26 locus (Fig. 3c
and Supplementary Table 2). All the mice were monitored for
tumour development by magnetic resonance imaging (MRI;
Fig. 3d). We observed a dramatic acceleration of tumorigenesis in
PK mice receiving the 15-sgRNA mix, with animals starting to
succumb to pancreatic cancers 4 weeks PE. Seven out of 13 mice
(54%) developed tumours within 24 weeks PE in this group,
whereas no tumours were detected in PK mice transfected with
neutral sgRNAs by MRI (n¼ 8; Po0.016; log-rank test; Fig. 3e).
Examples of pancreatic cancers with different histopathologic
characteristics (well/moderately differentiated to undifferentiated
or sarcomatoid pancreatic cancers) and liver metastases are
shown in Fig. 3f–k. To exclude the possibility that sarcomatoid
tumours are in fact sarcomas arising from CRISPR/Cas9 targeted
fibroblasts, we performed IHC staining of the epithelial marker
cytokeratin 19 (CK19) and E-cadherin. These experiments
confirmed the origin of dedifferentiated sarcomatoid cells from
CK19-positive pancreatic ductal structures (Fig. 3k). In addition,
recombination of the ‘stop’ cassette at the KrasLSL-G12D/þ allele
(mediated by pancreas-specific Ptf1aCre/þ ) was detectable in all
primary cell cultures derived from these tumours.
Multiplexed CRISPR/Cas9 for combinatorial gene targeting.
To examine the induction of mutations by CRISPR/Cas9, we
performed NGS of PCR-amplified target sites in primary pan-
creatic tumours and healthy control tissue. Because sequencing
reads with large deletions show only poor overlap with the
reference genome built, they are often filtered out during map-
ping by standard bioinformatics tools. We have therefore used
manually inspected/mapped capillary sequencing data to develop
optimized algorithms for NGS-based high-throughput CRISPR/
Cas9-induced indel detection in PCR products (see ‘Methods’
section). We have not found mutations (above sequencing error
rates) at sgRNA target sites in non-tumour pancreatic tissue
surrounding pancreatic cancers in electroporated mice (Fig. 4a).
This was expected because of the low number of cells to which
CRISPR/Cas9 is delivered by electroporation. Mutations induced
in these few cells are not detectable by ultra-deep sequencing,
because their frequency is far below the sequencing error rate.
In contrast to normal pancreatic tissue, all tumours had high-
frequency indels at multiple sgRNA target sites (Fig. 4a and
Supplementary Data 1), reflecting clonal expansion of CRISPR/
Cas9-induced driver mutations to give rise to cancer. We used
NGS to determine mutant read frequencies at target sites (MRFs;
defined as the fraction of mutant sequence reads/all reads at
individual target loci). In Fig. 4a, multiple mutations at individual
target sites are presented in a simplified way as cumulative MRFs
in each tumour. A detailed presentation of the type and frequency
of mutations at individual target sites is shown in Supplementary
Fig. 2 for each cancer.
The size of deletions and insertions ranged from 1 to 363 and 1
to 32 bp, respectively (Fig. 4b). Indel size and frequency correlated
inversely. The majority of indels were small and located at the
position of the Cas9-induced double-strand break (1–5 bp
upstream of PAM). Examples are shown in the relevant sequence
context in Fig. 4c. Large indels are also detectable by gel
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Figure 3 | CRISPR/Cas9-based pancreatic multiplex-mutagenesis and cancer induction in Ptf1aCre/þ ;KrasLSL-G12D/þ mice. (a) In vitro surveyor
nuclease assays showing cutting efficiencies of sgRNAs chosen for in vivo experimentation. Controls were transfected with neutral sgRNAs targeting the
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electrophoresis (Fig. 4c). There was a strong bias towards
deletions (90%) versus insertions (10%) as a result of repair by
non-homologous end joining (Fig. 4b).
Each cancer displayed indels in several target genes, reflecting
transfection of the cell of origin with multiple sgRNAs (Fig. 4a).
Seven to 14 out of 15 targeted genes, were mutated
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simultaneously in individual cancers, demonstrating (i) the high
efficiency of multiplexed CRISPR/Cas9 vector co-delivery to
individual cells and (ii) the high efficiency of gene editing by
transiently expressed CRISPR/Cas9 in pancreatic cells. This
suggests broad applicability of the method for combinatorial
gene targeting in the pancreas, for example, to explore synergistic
interactions of cancer genes.
We have recently exploited CRISPR/Cas9 multiplexing for
forward genetic screening in the mouse liver29. To this end, we
used hydrodynamic tail vein injection, which allows multiplexed
vector delivery to millions of cells, each obtaining a random
combination of few or many sgRNAs. This generates a huge
population of cells with enormous genetic complexity, thus
supporting forward genetic screening by positive selection.
Electroporation-based multiplexed CRISPR/Cas9 mutagenesis
in the pancreas differs however from the method deployed in the
liver in two key aspects: First, the number of targeted cells is
extremely low (few hundred per pancreas) and second, the
efficiency of multiplexed vector delivery to individual cells is
extremely high (7–14 sgRNAs per cell; including ‘neutral’
sgRNAs; see the high frequency of control Rosa26 indel
induction). Therefore, the total complexity of mutagenesis in
this setting is low and not appropriate for large-scale forward
genetics (and accordingly, no genotype/phenotype correlations
could be made in this small cohort). Instead, the methodology
will dramatically change our ability to perform complex
hypothesis-driven reverse genetics that is not feasible with other
model systems. Studying complex tumour-suppressor gene
interactions in a scenario of sporadic tumorigenesis is becoming
feasible not only in a high-throughput manner, but without any
germline genetic engineering and years of intercrosses. In
addition, somatic CRISPR/Cas9 genome engineering in inbred
adult mice overcomes the problem of unpredictable phenotypic
variation in mixed backgrounds, which is an important
confounder in multiallelic crosses of transgenic mice.
Multiplex-CRISPR/Cas9 for in vivo negative-selection screening.
The only target gene that was not mutated in CRISPR/Cas9-
induced cancers was Brca2, despite the fact the Brca2 sgRNAs are
functional and were shown to mediate indel formation with
similar efficiencies to other sgRNAs in vitro (Fig. 3a). This
suggests negative selection of Brca2 inactivation. Indeed,
homozygous Brca2 inactivation was shown to inhibit KrasG12D-
dependent PDAC formation, but promoted tumorigenesis in a
Trp53 mutant background, when Trp53-dependent cell cycle
checkpoints are altered in the mouse34,35. In addition, in human
pancreatic cancers, somatic Brca2 inactivation is invariably
associated with P53 mutations2. We suspect that similar
assumptions might also be true for Brca1, for which
homozygous disruption was only observed in one CRISPR/
Cas9-induced (Trp53-mutant) cancer. These data show that for
the first time negative-selection screening becomes feasible in the
mouse pancreas, providing unique opportunities to address a
wide variety of biological questions. The approach could be
exploited, for example, to systematically explore synthetic
lethality and therapeutic vulnerabilities in vivo.
Allelic status of CRISPR/Cas9-induced mutations. Deducing
homo- or heterozygousity of CRISPR/Cas9-induced mutations
from sequencing data (MRFs) is complex and can be confounded
by different factors. First, the high stromal component of
pancreatic cancers and the inter-tumour variability of stromal
reactions makes it difficult to assign wild-type sequence reads to
cancer versus stromal cells. To address this issue, we have
generated primary cell cultures (hereafter referred to as
‘cell lines’) from six tumours and compared their MRFs.
Supplementary Fig. 3 shows that cumulative MRF values
at individual target sites clearly discriminated between full
(not wild-type sequence) or heterozygous/partial target gene
inactivation in cell lines, but not in cancer tissue.
A second level of complexity arises from the frequent
occurrence of poly- and aneuploidy in pancreatic cancer. We
have, therefore, also performed multispectral karyotyping (multi-
colour fluorescence in situ hybridization (M-FISH)) of all the cell
lines and combined M-FISH/sequencing data to obtain an exact
picture of chromosome numbers and mutations related to each
target site. Tu1 is an example of a cancer with a stable diploid
karyotype. Accordingly, it showed a maximum of two indepen-
dent indels per target site. Examples of chromosomes/target sites
with homo-, hetero- or no mutation are shown in Fig. 4e (the full
karyotype and mutation spectrum is shown in Supplementary
Fig. 4). In contrast, Tu2 had often more than two indels per target
site (up to five; Fig. 4e and Supplementary Fig. 4), which could be
reconciled by its poly/aneuploidy karyotype. For example, the
frequency of the wild-type and the three different indel sequences
at Rosa26.2 could be assigned to the seven copies of chromosome
6 (Fig. 4e; see Supplementary Fig. 4 for more examples). The indel
pattern in this tumour also shows that polyploidy was already
present at the time of transient CRISPR/Cas9 expression. Overall,
in depth analysis of MRFs in cancer cell cultures revealed that in
76% of cases CRISPR/Cas9 mutagenesis induced complete gene
inactivation, whereas in 24%, at least one wild-type allele was
retained (Fig. 4d).
Phylogenetic tracking of metastatic disease. One limitation
of standard pancreatic cancer models (for example, the widely
used Kras/Trp53 double-mutant model) is multifocal cancer
Figure 4 | Target site mutations in CRISPR/Cas-induced cancers. (a) Indels and allelic status at each target site in electroporated healthy pancreatic
tissue (PancTi), PDAC cell lines (Tu1-6) and primary tumour tissue (Tu7 Ti). Numbers in boxes indicate for each target site mutant read frequencies
(MRFs; defined as the fraction of mutant sequence reads/all reads at individual target loci). Multiple mutations per target site are presented as one
combined MRF. A more detailed presentation of the different mutations at individual target sites is shown in Supplementary Fig. 2. Red and blue boxes
indicate complete or partial inactivation of targeted loci, respectively. A target locus was defined to be only partially inactivated if at least one chromosome
with non-mutated wild-type sequence was retained. For tissue (brown boxes), assumptions about full/partial inactivation cannot be made. Grey boxes
designate a lack of mutations at target sites. The asterisk stands for a large deletion at the Cdkn2a locus with fusion of Cdkn2a-ex1b and Cdkn2a-ex2
(see also Fig. 6). White boxes (Tu3) indicate electroporation without Rosa26.1 and Rosa26.2 control guides. (b) Spectrum and distribution of indel types and
sizes in all sequenced tumours. Del, deletion; Ins, insertion. (c) Examples and sequence context of CRISPR/Cas9-induced homozygous (homoz) mutations
at target sites. Large deletions were also detectable by PCR, showing additional shortened products. PAM, protospacer adjacent motive; ex, exon and Co,
control. (d) Allelic status at target sites across tumours. Homozygousity was defined by a lack of wild-type sequence reads in cancer cell cultures. Het,
heterozygous. (e) Examples of mutational spectra in a diploid (Tu1) and a poly-/aneuploidy cancer (Tu2). M-FISH and target site sequencing were
performed on the cell lines. Results are shown for three representative target genes. MRFs of target site mutations are assigned to individual chromosomes.
The existence of more than two mutations at a target site in Tu2 reflects early polyploidization during transient CRISPR/Cas9 expression. Comprehensive
data for all chromosomes are shown in Supplementary Fig. 4.
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms10770 ARTICLE
NATURE COMMUNICATIONS | 7:10770 |DOI: 10.1038/ncomms10770 |www.nature.com/naturecommunications 7
development, which confounds/limits evolutionary studies or
phylogenetic tracking of metastatic spread. We hypothesized that
the CRISPR/Cas9 mutation pattern could be exploited to track
the evolution of metastases in mice with multiple independent
cancers. To this end, we performed extensive geographic
sampling of a large tumour mass (B1.5 cm) in one animal and
generated cell cultures from eight tumour regions (Fig. 5 and
Supplementary Fig. 5). NGS of target sites in primary cancer
tissue and in corresponding cell cultures revealed two indepen-
dent primary cancers, as defined by (i) the different combination
of affected genes and (ii) differences in the indel types and
locations at individual target sites. We found that the largest part
(95%) of the tumour mass originated from Tu1 (Fig. 5 and
Supplementary Fig. 5). Only one out of the eight biopsies (biopsy
1) showed an indel pattern that indicated the presence of an
additional tumour. We generated a total of 14 single-cell clones
from the primary cell culture of biopsy 1, which made it
possible to clearly define Tu2 at the genetic level (Fig. 5 and
Supplementary Fig. 5).
We also collected nine metastatic nodules and generated
corresponding cell cultures. CRISPR/Cas9-induced indel patterns
revealed that both cancers contributed to the metastatic
phenotype to a similar extent (50% of nodules originating from
Tu1 and 50% from Tu2; Fig. 5 and Supplementary Fig. 5). All
together, these results show that CRISPR/Cas9 multiplexing and
indel analysis is a very accurate and inexpensive approach (as
compared with CGH or exome-sequencing) to phylogenetically
track metastases.
Off-target effects in CRISPR/Cas9-induced cancers. To
examine whether transient CRISPR/Cas9 expression leads to
off-target cutting, we have sequenced each sgRNA’s top five off-
target sites and at least three exonic off-targets (Supplementary
Tables 3 and 4). The analysis of amplicon-based NGS data from
648 positions (108 potential off-targets per cancer; in six cell
lines) revealed exclusively wild-type sequences at these predicted
off-target sites. Thus, we conclude that undesired off-target
effects are negligible in our experimental setting of transient
CRISPR/Cas9 expression.
Engineering of chromosomal rearrangements by CRISPR/Cas9.
Human pancreatic cancer is characterized by a high
complexity of chromosomal alterations, including numerical
chromosomal aberrations, intra-chromosomal deletions, un-
balanced inter-chromosomal translocations or other more
complex rearrangements, such as chromothripsis2,6,36–38. The
extent of structural variation reported in different studies varies to
some extent (possibly because of the use of different pancreatic
cancers and methodologies), although all report a high frequency
of complex karyotypes. In accordance, we found a median of 139
intra-chromosomal deletions/amplifications and eight inter-
chromosomal translocations per tumour in 23 human PDAC
cell lines, which we have screened using high-density array
comparative genomic hybridisation (aCGH) and M-FISH
(Supplementary Fig. 6). Translocations most frequently affected
chromosomes harbouring key pancreatic tumour suppressors,
such as CDKN2A (Chr9) or P53 (Chr17). In accordance,
recent evidence suggests that structural variations in PDAC are
non-random: inter-chromosomal translocations, for example, are
predominantly unbalanced and typically affect (disrupt) key
tumour suppressor genes, including CKDN2A, SMAD4 or P53
(refs 37–39).
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Figure 5 | Phylogenetic tracking of CRISPR/Cas9-induced metastatic PDAC. A large (B1.5 cm) CRISPR/Cas9-induced PDAC was geographically
sampled to generate cancer cell cultures (squares) from eight tumour regions. Sequencing (Seq.) of these eight cell cultures suggested the existence of two
independent tumours: Tu1, in all cultures (1–8), and Tu2 in culture 1. Further sequencing of 14 single cell clones derived from region 1 (rhombuses)
confirmed the existence of two independent primary cancers: see combined MRFs for single cell clones 1 and 8 (Tu1) and 5 and 12 (Tu2). Nine liver
metastases (liv met) were collected to generate cancer cell cultures (circles). Mutation patterns showed that both tumours produced metastases to a
similar extent. Details about mutation types at target sites are shown in Supplementary Fig. 5.
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We and others have previously shown that CRISPR/Cas9
can induce large intra-chromosomal deletions in vivo29,40,41.
To comprehensively analyse whether multiplexed CRISPR/Cas9
mutagenesis can induce complex genomic rearrangements in the
pancreas, we have first performed a systematic PCR-based screen
in all primary tumours for potential intra-chromosomal deletions
on chromosomes with more than one sgRNA target site
(Supplementary Fig. 7). Out of the nine possible fusions, we
found evidence for one 18-Kb deletion in Tu4: caused by sgRNAs
targeting Cdkn2a-ex1b and Cdkn2a-ex2, which lead to the
inactivation of both p16Ink4a and p19Arf (Fig. 6a).
In addition, we performed aCGH because we have previously
observed that the boundaries of large CRISPR/Cas9 deletions
occasionally go beyond the sgRNA target sites, and might
therefore be missed by the above-described ‘fusion-PCR’ screen-
ing approach. aCGH also allowed a more comprehensive
genome-wide analysis of chromosomal alterations. These
experiments confirmed the above-described deletion at the
Cdkn2a locus in Tu4 and identified another similar deletion in
Tu2, which was not detected by the fusion PCR approach
(but is very likely to be CRISPR/Cas9 induced). We also found
44.4, 28.6 and 5.0Mb deletions that were linked to unbalanced
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Figure 6 | Chromosomal rearrangements in cancers induced by CRISPR/Cas9-multiplexing. (a) CRISPR/Cas9-induced intra-chromosomal deletion of an
18 Kb fragment by combinatorial sgRNA targeting. PCR screening for all possible intra-chromosomal fusions on chromosomes with more than one sgRNA
target site was performed across pancreatic cancers. The gel image shows respective PCRs at the Cdkn2a locus. sgRNA target sites in Cdkn2a-ex1/ex2 and
PCR primers are indicated by red arrow heads and black arrows, respectively. Sanger sequencing confirmed the ex1b-ex2 fusion. del, deletion; ex, exon.
(b,c) M-FISH of cell lines revealed unbalanced inter-chromosomal translocations induced by combinatorial CRISPR/Cas9 targeting in two out of six
cancers. Fusion products were detected by PCR and sequencing. Arrows indicate primer positions. del, deletion; der, derivative; t, translocation.
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translocations, as described below in Tu2 and Tu5. In summary,
three out of six tumours had large CRISPR/Cas9-induced
deletions (Tu2, Tu4, Tu5), whereas three tumours had ‘silent’
aCGH profiles.
To screen for CRISPR/Cas9-induced inter-chromosomal
translocations, we performed M-FISH in the six cell lines. We
found unbalanced translocations in two out of these six cases. An
unbalanced reciprocal translocation in Tu2 involved chromo-
somes 4 and 18 (Fig. 6b). Sequencing of fusion products revealed
a der(4)t(4;18) translocation (fusion between Cdkn2b and Apc)
and a der(18)t(4;18) translocation (fusion between Apc and
Arid1a) (Fig. 6b). A translocation in Tu5 (der(19)t(17;19)) was
non-reciprocal (between Pten and Arid1b; Fig. 6c) and led to loss
of parts of Chr17 and Chr19. In all the cases, the translocations
were clonal and breakpoints were at the exact sgRNA target sites,
confirming that they are CRISPR/Cas9 induced.
On average, there was less than one CRISPR/Cas9-induced
deletion or translocation per tumour, which represents only a
small fraction of the total number of aberrations observed in
Ptf1aCre/þ ;KrasLSL-G12D/þ -induced pancreatic cancers (B20.5
structural aberrations per tumour; n¼ 40; profiling performed by
aCGH. In addition, we found that CRISPR/Cas9-dependent
chromosomal aberrations did not have a negative impact on the
quality of other applications, for example, on the negative-
selection screen.
The impact of translocations on genomic instability in
pancreatic cancer is unclear. It is striking that the majority of
CDKN2A and SMAD4 inactivations in human PDAC are a result
of translocations rather than simple intra-chromosomal deletions,
as seen in most other cancer types39. This raises the possibility
that genome imbalance in itself could be an important driver
of pancreatic tumorigenesis. Indeed, recent studies in yeast
and eukaryotic cells suggested that numerical and unbalanced
structural chromosomal aberrations can drive genomic instability
(for example, the acquisition of new rearrangements)42,43.
However, functional analysis of such phenomena at an
organismal level in the context of cancer has not been possible
to date. Although genomic instability can be nonspecifically
induced/elevated by genetic changes of stability genes (for
example, Cenpe, Mad2, Trp53)44, these genes (i) do not allow
locus-specific induction of structural variation and (ii) have
additional independent cancer-relevant functions, confounding
the interpretation of resulting phenotypes.
We show here for the first time that such limitations can be
overcome. The structural variations associated with CRISPR/Cas9
tumour suppressor gene inactivation suggests that there might be
selective pressure beyond simple gene disruption for complex
rearrangements to occur in pancreatic cancer. Our experiments
show that multiplexed CRISPR/Cas9 will allow a systematic
analysis of such questions directly in vivo. In human cancer, the
frequency of DNA breakage is the parameter that best predicts
the likelihood of a particular genomic site being involved in a
translocation45. Therefore, we expect that using multiple sgRNAs
targeting a specific locus, might substantially increase the
efficiency of inducing specific inter-chromosomal translocations.
Discussion
Our studies show multiplexed somatic genome editing and cancer
induction in the pancreas, which will provide access to the genetic
complexity of pancreatic cancer. We demonstrate several major
types of applications that require multiplexing, including
(a) high-throughput functional analysis of complex cancer gene
interactions/networks, (b) phylogenetic tracking of metastatic
disease, (c) in vivo negative selection screening and (d) direct
in vivo chromosome engineering.
Transfection-based multiplexed CRISPR/Cas9 delivery
developed in this study has unique features and a number
of advantages over other (for example, viral) delivery
approaches27,28. First, in contrast to viral approaches, it allows
highly efficient delivery of multiple sgRNAs per cell to enable the
different applications that require multiplexing. Second, the
protocol is fast and allows high-throughput studies; there is no
need for time-consuming virus production/testing, as naked DNA
can be injected. Third, off-target effects are not being observed,
presumably because of the transient nature of transfection, which
contrasts the long-term Cas9 and sgRNA expression from
genome-integrated viral or transposon-mobilized DNA. Fourth,
there is no risk of virally infected cells being eliminated by
adaptive immunity. Fifth, insertional mutagenesis is not an issue,
as sometimes observed with viral or transposon-based delivery
approaches. Finally, there is no need for biosafety level two
experimentation as required for many viral delivery approaches.
Next generation sequencing of human cancers and genome-
wide transposon-based genetic screening studies have revealed
the extensive complexity and heterogeneity of the genetic
networks underlying pancreatic tumorigenesis2–7. Multiplexed
CRISPR/Cas9 mutagenesis in adult mice will now allow to
systematically validate such data in a high-throughput manner
and to interrogate if and how putative cancer genes collaborate
during tumour initiation, progression and metastatic spread
in vivo. This will dramatically enhance our ability to functionally
annotate pancreatic cancer genomes and signalling networks.
We have targeted tumour suppressor genes in this study, but in
principle, oncogenes can be targeted somatically too: either by
conditional somatic gene transfer using avian retroviral vectors46
or by delivering re-engineered Cas9 as a programmable
transcription factor, which can be used to activate gene
expression (for example, nuclease-deficient Cas9 fused to the
VP64 transactivation domain47,48).
We developed for the first time an approach for negative-
selection screening in the mouse pancreas. As proof-of-principle,
we showed selection against Brca2 inactivation, confirming
previous reports on the inhibition of KrasG12D-dependent PDAC
formation by Brca2 inactivation (in a Trp53 proficient context) in
the mouse34,35. Negative-selection screening provides unique
opportunities to address a wide range of biological questions. It
could be exploited, for example, to discover essential Ras
downstream targets and vulnerabilities in pancreatic cancer, or
to systematically explore synthetic lethality in vivo.
We found that the complex mutational signature of multi-
plexed CRISPR/Cas9 genome engineering can be exploited for
phylogenetic tracking of metastatic disease. In principle, this
approach can also be extended to study the timing of systemic
dissemination or to develop early detection tools based on the
monitoring of circulating tumour DNA. Such CRISPR/Cas9
applications could substantially facilitate not only studies into the
genetic basis of cancer evolution and metastasis but also into
translational aspects of the disease.
Chromosome engineering has been the biggest challenge in
genetic manipulation of the mouse germ line49. We found
that complex rearrangements were induced by multiplexed
CRISPR/Cas9 in a subset of cancers. We observed not only
intra-chromosomal deletions but also provide the first example
of targeted somatic engineering of inter-chromosomal
translocations in a higher organism. This will have a profound
impact on our ability to study if and how pancreatic
tumorigenesis is driven by chromosomal imbalance, a hallmark
of pancreatic cancer. CRISPR/Cas9-based chromosome
engineering will also facilitate the functional analysis of PDAC-
associated noncoding regions emerging from GWAS and
sequencing studies2,50,51. Finally, these results also pinpoint
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limitations of CRISPR/Cas9 multiplexing in the pancreas, thus
providing guidance for its accurate use: particularly in
experimental settings where structural rearrangements are not a
desired outcome, the level of in vivo multiplexing will have
limitations and the occurrence of rearrangements will need to be
tested for.
Multiplexed CRISPR/Cas9 genome editing will not only
increase the speed/efficiency with which pancreatic cancer can
be modelled in mice for biological and preclinical research, but
the low-frequency mosaic transfection pattern described here also
better recapitulates the sporadic nature of human tumorigenesis
than traditional knockouts.
Methods
Design of sgRNA sequences. Consensus coding sequences (CCDS) for each
target gene were downloaded from ensembl.org and sgRNA cassettes generated
using the CRISPR design tool (http://crispr.mit.edu). sgRNA sequences are shown
in Supplementary Table 5.
Cloning of CRISPR-SB. For delivery of CRISPR/Cas9 components, we used a
modified one-vector system pX330 (Addgene #42230) with Sleeping Beauty
inverted terminal repeats flanking sgRNA and Cas9 expression cassette
(CRISPR-SB)29. The transposon repeats allow stable genomic integration of the
CRISPR construct when co-delivered with a transposase, an option not pursued in
this study. Annealed sgRNA oligonucleotides (Supplementary Table 5) were cloned
into BbsI-opened CRISPR-SB vector52.
SURVEYOR assay for individual sgRNA cleavage efficiency. To determine
individual sgRNA cleavage efficiency in our CRISPR-SB vector system, we used
the mouse pancreatic cancer cell line PPT-4072 that contains intact loci at all
target sites. The cell line was cultured in RPMI (Thermo Fisher Scientific Inc.)
supplemented with 10% fetal bovine serum (Biochrome) and 1 Pen Strep
(penicillin 50 unitsml 1, streptomycin 50 mgml 1; Thermo Fisher Scientific Inc.).
A total of 50,000 cells were seeded in a 12-well plate the day before transfection.
500 ng of respective CRISPR-SB vector and 200 ng of pLentiX1-Puro (Addgene
#17297) vector were co-transfected overnight with 25 ml Lipofectime 2000 reagent
(Life Technologies). The cells were selected with 4 mgml 1 puromycin (Thermo
Fisher Scientific Inc.) for approximately 72 h, lysed with DirectPCR lysis kit
(Qiagen) and amplified by TaKaRa Ex Taq polymerase (Clontech) using primer
pairs listed in Supplementary Table 6. A total of 250 ng of each PCR product was
adjusted in a total of 12ml 1 TaKaRa reaction buffer. Heteroduplex formation
and SURVEYOR nuclease assay (Transgenomic) were performed according to
manufacturer’s instructions. Cas9-mediated indel frequency was calculated on the
basis of the fraction of enzymatically cleaved DNA, as determined by integrated
intensity of gel bands53.
Animal experiments. Mouse lines used in this study include Ptf1aCre/þ (ref. 32),
KrasLSL-G12D/þ mice33 and Rosa26mT/mG mice30 (all on a mixed C57BL/6J;129S
background). Animals were housed and maintained under specific-pathogen-free
conditions according to the institutional guidelines. All animal studies were
conducted in compliance with European guidelines for the care and use of
laboratory animals and were approved by the Institutional Animal Care and
Use Committees (IACUC) of Technische Universita¨t Mu¨nchen, Regierung von
Oberbayern and the UK Home Office.
Surgical procedures and in vivo electroporation. In principle, in vivo electro-
poration-based transfection is widely applicable in many organs, for example,
muscle54, liver55, lung56, brain26. For surgery, 8-to-15-week-old mice were
anaesthetized with a combination of medetomidine (0.5mg kg 1), midazolam
(5.0mg kg 1) and fentanyl (0.05mg kg 1, MMF). The left flank was carefully
shaved, the eyes protected with ointment and the abdomen disinfected. When
anaesthesia was complete, an B1.5-cm left-lateral incision caudal to the spleen
was made, and the pancreas located, which was then carefully pulled out of the
abdomen to make it accessible for intraparenchymal injection. Plasmid mixture
was administered slowly using a 27G cannula at a depth of 3–4mm. Four mg of
each CRISPR-SB vector (60 mg for 15 sgRNA mix or 8 mg for Rosa26 sgRNA
control mix in a total volume of 50 ml) was delivered. The cannula was left in this
position for at least 30 s to avoid leakage of the bleb. For in vivo electroporation, the
Nepa21 square-pulse generator connected to forceps-type electrodes equipped with
3mm2 disks (CUY650P3, Nepa Gene Co., Ltd., Ichikawa, Chiba, Japan) was used.
For electroporation, the injection site was carefully sandwiched by the forceps-type
electrodes. To limit tissue damage, a maximum voltage of 50V was used. In cases
where the Joule heat measurement during poring pulses (Pp) was less than 0.15
Joule, we applied a second series of pulses to increase transfection efficiency. The
Nepa21 instrument is capable of generating exact square-pulses facilitating efficient
DNA transfer to cells in vivo. During electrophoretic transfection, two different
types of pulses are applied to the organ (Fig. 1b,c). Owing to the higher voltage, the
first series of pulses (Poring pulse, Pp) introduces pores into the plasma membrane
of the cells. The second series contains lower amplitudes that are extended
(Transfer pulse; Tp), which facilitates the transfer of DNA particles into the
cytoplasm. After electroporation, the pancreas and spleen were carefully placed
back in their anatomical position and covered with 1 phosphate-buffered saline
(PBS; Life Technologies) to avoid organ adhesion. The peritoneum was closed with
interrupted sutures (5-0 Ethilon) and the skin with wound clips. The mice were
kept in a 37 C heating chamber until they woke up.
Efficiency of in vivo electroporation in the murine pancreas. Transfection
efficiency was tested by injection of 60 mg GFP expressing plasmid pcDNA6.2
(LifeTech), mixed 1:1 with endoscopic marker (GI Supply) into 8-to-15-week-old
wild-type mice (C57BL/6J). Endoscopic marker contains a sterile, non-pyrogenic
suspension consisting of highly purified carbon particles to create a permanent
mark of labelled tissue. To identify GFP-expressing cells, the mice were killed 2
days PE. For dissection, the area of injection was located by endoscopic marker.
Pancreatic tissue was fixed in formalin solution, embedded in paraffin and cut in
2 mm sections. Every other section was sampled and IHC against GFP performed
(Supplementary Table 7). Overall, 12 out of 24 specimens were counted for
GFP-positive cells.
Long-term surviving transfected pancreatic cells. To determine the number of
successfully transfected long-term surviving pancreatic cells 8-to-15-weeks-old
Rosa26mT/mG mice were electroporated using 30 mg PGK-Cre vector (Addgene
#11543) or non-vector controls and pancreata were removed 7 days PE.
Cre-mediated recombination of the Rosa26mT/mG allele results in excision of mT
(membrane-targeted tdTomato) and expression of mG (membrane-targeted GFP).
Tissues were fixated in 4% paraformaldehyde without methanol for 1 h and
subsequently dehydrated in 15 and 30% sucrose dissolved in PBS until tissue sunk.
Dehydrated tissues were embedded in Tissue-Tek (Sakura) and snap frozen in
liquid nitrogen for cryosectioning. To analyse recombination events in the
electroporated area of the pancreas, the marked area of injection was completely
sampled: every other 10 mm section was analysed. Therefore, specimens were
counterstained with DAPI (Thermo Fisher Scientific Inc.) and recombined
GFP-positive cells were counted by fluorescence microscopy.
Nested PCR to detect recombination of the Rosa26mT/mG allele. Nested PCR
was performed to verify Cre-mediated genetic recombination of the Rosa26mT/mG
allele in reporter mice. DNA from the electroporated site of pancreata was isolated
and 4100 ng DNA submitted to the first PCR run using Taq Polymerase (VWR
International; 40 cycles; Ta¼ 62 C; Supplementary Table 8). One ml of PCR
product, or 1 ml of a 1:105 dilution of the positive control, were taken for the second
amplification step using the nested primer set (30 cycles; Ta¼ 62 C;
Supplementary Table 8). Nested PCR products were either size separated on a 1.5%
agarose gel or purified (QIAquick PCR Purification Kit, Qiagen) for validation of
Cre-mediated Rosa26mT/mG recombination by Sanger Capillary sequencing.
MRI screening. MRI was performed on a 3-Tesla clinical MRI Philips Healthcare
system (Ingenia 3 T) with human eight-channel wrist coil (SENSE Wrist coil 8
elements) following previously described protocol that was adapted for 3 T
scanners. Five to 10 weeks post electroporation, the mice were screened once per
month by MRI. For this, longitudinal T2-weighted (T2w) turbo spin-echo imaging
(slice thickness¼ 0.7mm, in-plane resolution¼ 0.3 0.38mm2, TR/TE¼ 4,352
ms/101ms, TF¼ 21, NSA¼ 9) was performed for tumour detection. The mice
were killed when tumours reached a size larger than 2mm diameter57.
Histology and Immunohistochemistry. Preparation of formalin-fixed
paraffin-embedded tissue was performed as described above for efficiency testing.
Specimens were haematoxylin and eosin stained according to standard protocols.
Pretreatment procedures, primary antibodies and dilutions for IHC are listed in
Supplementary Table 7. For visualization, either horseradish peroxidase-labelled
secondary rabbit anti-rat antibody (1:1,000, Jackson Immuno Research) or
secondary mouse anti-rabbit antibody (1:300, Dako) were used and detection was
performed by following the manual of the Bond Polymer Refine Detection Kit on a
Bond Max staining roboter (Leica).
Establishment of primary cell lines. For the isolation of primary murine cell
lines, tumour tissue from the primary tumour or liver metastases were washed in
PBS, cut into small pieces, transferred in collagenase digestion media (200Uml 1
Collagenase Type II (Worthington), 10% FBS, 1 Pen Strep (penicillin
50 unitsml 1, streptomycin 50mgml 1), 1% Fungizone (2.5 mgml 1) in RPMI
1640 medium (all Thermo Fisher Scientific Inc.)) and digested overnight at 37 C.
The following day, released cells were seeded in a six-well plate and passaged in
RPMI 1640 medium containing 10% FBS, 1 Pen Strep and 1% Fungizone.
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DNA isolation and Sanger sequencing. DNA was isolated from tissue samples
(stored at  20 C in RNAlater (Sigma-Aldrich)) or frozen cell pellets of
corresponding cell lines using the DNeasy Blood and tissue kit (Qiagen).
Amplification of target genomic regions was performed using Q5 High-Fidelity
DNA Polymerase (New England Biolabs). For Sanger capillary sequencing, the
PCR products were purified (QIAquick PCR Purification Kit, Qiagen) and each
PCR reaction was sequenced individually using the corresponding forward primer.
Primers were chosen to amplify a PCR product of approximately 400 to 500 base
pairs around the target site (Supplementary Table 6).
Next-generation amplicon sequencing. DNA extraction and amplification of
genomic target (Supplementary Table 6) or off-target loci (Supplementary Tables 3
and 4) was performed as described for Sanger sequencing. All amplified target loci
(20 ml reaction volume) were pooled and purified (QIAquick PCR Purification Kit,
Qiagen). Library preparation with NEBNext Ultra DNA Library Prep Kit for
Illumina and quantification was conducted as described previously58. Briefly, after
end repair and A-tailing, Illumina paired end adaptors were ligated and the
individual sample pools were barcoded with 12 cycles of PCR (sequences in
Supplementary Table 6). Barcoded samples were pooled and the final library
quantified with qPCR for sequencing on Illumina MiSeq (300 bp, paired end).
Bioinformatic analyses. MiSeq Illumina paired 300 nucleotide reads were
mapped with BBMAP short read aligner (http://bbmap.sourceforge.net) using default
settings onto mm10 assembly. Only this particular aligner was able to map correctly
large deletions 4100 bp in comparison to a number of other aligners tested. BAM
files were sorted and indexed with samtools (v0.1.19; ref. 59). After mapping, only
paired reads (about 3% were unpaired) were extracted based on bitwise flag 0 2
resulting in BAM files containing only correctly paired reads. Samtools (v0.1.6) pileup
command with option (-i) was used to display lines containing indels to obtain data in
pileup format with the number of reads covering sites. Pileup files were processed
with VarScan (v2.3.6) pileup2indel command60. Detected indels were only considered
to be true if supported by more than 100 mutant reads. A list of all filtered indels used
for mutation analysis is given in Supplementary Data.
Intra- and inter-chromosomal rearrangement PCRs. Every possible
intra-chromosomal combination of the CRISPR-SB sgRNAs was tested by
performing TaKaRa Ex Taq PCR on all the tumour samples. Inter-chromosomal
rearrangements (translocations) were tested as indicated by M-FISH. In brief, 50 ng
of genomic DNA was used for 30 ml PCR reaction volume with primer pairs
indicated in Supplementary Table 6. The resulting PCR product was gel purified
(Gel purification Kit, Qiagen) and sequenced by Sanger Capillary sequencing.
M-FISH analysis. To analyse inter-chromosomal fusions/rearrangements in
pancreatic tumour cell lines derived from mice electroporated with CRISPR-SB
vectors, multicolour fluorescence in situ hybridization (M-FISH) was carried out as
described before61.
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